Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

The Phase I trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal ...

A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will ...

OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

Exclusive global license outside of Greater Chinafor MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) ...

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...

Innate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the ...

US clinical-stage biotech ArriVent BioPharma has entered into an exclusive license agreement with Shanghai-based Lepu ...

LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- The Global Antibody Drug Conjugate market was valued at USD 10.13 billion in 2023, growing at a CAGR of 14.37% during the forecast ...

The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12 ...